FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1089-1096 September 9, 2004 Number 11 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Liu, B. A. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Oral erythromycin prolongs cardiac repolarization and is associated with case reports of torsades de pointes. Because erythromycin is extensively metabolized by cytochrome P-450 3A (CYP3A) isozymes, commonly used medications that inhibit the effects of CYP3A may increase plasma erythromycin concentrations, thereby increasing the risk of ventricular arrhythmias and sudden death. We studied the association between the use of erythromycin and the risk of sudden death from cardiac causes and whether this risk was increased with the concurrent use of strong inhibitors of CYP3A.

Methods We studied a previously identified Tennessee Medicaid cohort that included 1,249,943 person-years of follow-up and 1476 cases of confirmed sudden death from cardiac causes. The CYP3A inhibitors used in the study were nitroimidazole antifungal agents, diltiazem, verapamil, and troleandomycin; each doubles, at least, the area under the time–concentration curve for a CYP3A substrate. Amoxicillin, an antimicrobial agent with similar indications but which does not prolong cardiac repolarization, and former use of erythromycin also were studied, to assess possible confounding by indication.

Results The multivariate adjusted rate of sudden death from cardiac causes among patients currently using erythromycin was twice as high (incidence-rate ratio, 2.01; 95 percent confidence interval, 1.08 to 3.75; P=0.03) as that among those who had not used any of the study antibiotic medications. There was no significant increase in the risk of sudden death among former users of erythromycin (incidence-rate ratio, 0.89; 95 percent confidence interval, 0.72 to 1.09; P=0.26) or among those who were currently using amoxicillin (incidence-rate ratio, 1.18; 95 percent confidence interval, 0.59 to 2.36; P=0.65). The adjusted rate of sudden death from cardiac causes was five times as high (incidence-rate ratio, 5.35; 95 percent confidence interval, 1.72 to 16.64; P=0.004) among those who concurrently used CYP3A inhibitors and erythromycin as that among those who had used neither CYP3A inhibitors nor any of the study antibiotic medications. In contrast, there was no increase in the risk of sudden death among those who concurrently used amoxicillin and CYP3A inhibitors or those currently using any of the study antibiotic medications who had formerly used CYP3A inhibitors.

Conclusions The concurrent use of erythromycin and strong inhibitors of CYP3A should be avoided.

Source Information

From the Division of Pharmacoepidemiology, Department of Preventive Medicine (W.A.R., S.M., K.H.), and the Departments of Medicine and Pharmacology, Divisions of Cardiology (K.T.M.), Clinical Pharmacology (K.T.M., S.S.N., C.M.S.), and Rheumatology (C.M.S.), Vanderbilt University School of Medicine; and the Geriatric Research, Education, and Clinical Center, Nashville Veterans Affairs Medical Center (W.A.R.) — both in Nashville.

Address reprint requests to Dr. Ray at cindy.naron{at}vanderbilt.edu.

Full Text of this Article

Related Letters:

Oral Erythromycin and the Risk of Sudden Death
Kaplan E. L., Winston A. P., Schoenholtz J. C., Harris J.-D., de Leon-Casasola O. A., Amory J. K., Amory D. W. Sr., Ray W. A., Murray K. T., Stein C. M., Liu B. A., Juurlink D. N.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:301-304, Jan 20, 2005. Correspondence

This article has been cited by other articles:

• Dickerson, R. N., Mitchell, J. N., Morgan, L. M., Maish, G. O. III, Croce, M. A., Minard, G., Brown, R. O. (2009). Disparate Response to Metoclopramide Therapy for Gastric Feeding Intolerance in Trauma Patients With and Without Traumatic Brain Injury. JPEN J Parenter Enteral Nutr 33: 646-655 [Abstract] [Full Text]  
• Raj, S. R., Stein, C. M., Saavedra, P. J., Roden, D. M. (2009). Cardiovascular Effects of Noncardiovascular Drugs. Circulation 120: 1123-1132 [Full Text]  
• Gerber, M. A., Baltimore, R. S., Eaton, C. B., Gewitz, M., Rowley, A. H., Shulman, S. T., Taubert, K. A. (2009). Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis: A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics. Circulation 119: 1541-1551 [Abstract] [Full Text]  
• Arbogast, P. G, Ray, W. A (2009). Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res 18: 67-80 [Abstract]  
• Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., Stein, C. M. (2009). Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. NEJM 360: 225-235 [Abstract] [Full Text]  
• Crosbie, P. A. J., Woodhead, M. A. (2009). Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 33: 171-181 [Abstract] [Full Text]  
• Nallamothu, B. K., Hayward, R. A., Bates, E. R. (2008). Beyond the Randomized Clinical Trial: The Role of Effectiveness Studies in Evaluating Cardiovascular Therapies. Circulation 118: 1294-1303 [Full Text]  
• Cummings, P. (2008). Propensity Scores. Arch Pediatr Adolesc Med 162: 734-737 [Full Text]  
• Roumie, C. L., Mitchel, E. F. Jr, Kaltenbach, L., Arbogast, P. G., Gideon, P., Griffin, M. R. (2008). Nonaspirin NSAIDs, Cyclooxygenase 2 Inhibitors, and the Risk for Stroke. Stroke 39: 2037-2045 [Abstract] [Full Text]  
• Extramiana, F., Badilini, F., Sarapa, N., Leenhardt, A., Maison-Blanche, P. (2007). Contrasting Time- and Rate-Based Approaches for the Assessment of Drug-Induced QT Changes. J Clin Pharmacol 47: 1129-1137 [Abstract] [Full Text]  
• Hershman, D., Neugut, A. I., Jacobson, J. S., Wang, J., Tsai, W.-Y., McBride, R., Bennett, C. L., Grann, V. R. (2007). Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy. JNCI J Natl Cancer Inst 99: 196-205 [Abstract] [Full Text]  
• Kirchhof, P., Breithardt, G., Eckardt, L. (2006). Primary prevention of sudden cardiac death. Heart 92: 1873-1878 [Full Text]  
• Developed in Collaboration With the European Heart, , Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., Priori, S. G., Quinones, M. A., Roden, D. M., Silka, M. J., Tracy, C., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Antman, E. M., Anderson, J. L., Hunt, S. A., Halperin, J. L., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 48: e247-e346 [Full Text]  
• Writing Committee Members, , Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., Priori, S. G., Quinones, M. A., Roden, D. M., Silka, M. J., Tracy, C., ESC Committee for Practice Guidelines, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L., ACC/AHA Task Force Members, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Antman, E. M., Anderson, J. L., Hunt, S. A., Halperin, J. L., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2006). ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8: 746-837 [Full Text]  
• Metheny, N. A. (2006). Preventing respiratory complications of tube feedings: evidence-based practice.. Am J Crit Care 15: 360-369 [Abstract] [Full Text]  
• Wisialowski, T., Crimin, K., Engtrakul, J., O'Donnell, J., Fermini, B., Fossa, A. A. (2006). Differentiation of Arrhythmia Risk of the Antibacterials Moxifloxacin, Erythromycin, and Telithromycin Based on Analysis of Monophasic Action Potential Duration Alternans and Cardiac Instability. J. Pharmacol. Exp. Ther. 318: 352-359 [Abstract] [Full Text]  
• Ehret, G. B., Voide, C., Gex-Fabry, M., Chabert, J., Shah, D., Broers, B., Piguet, V., Musset, T., Gaspoz, J.-M., Perrier, A., Dayer, P., Desmeules, J. A. (2006). Drug-Induced Long QT Syndrome in Injection Drug Users Receiving Methadone: High Frequency in Hospitalized Patients and Risk Factors.. Arch Intern Med 166: 1280-1287 [Abstract] [Full Text]  
• American Heart Association, (2006). 2005 American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiovascular Care (ECC) of Pediatric and Neonatal Patients: Pediatric Advanced Life Support. Pediatrics 117: e1005-e1028 [Full Text]  
• Jespersen, C. M, Als-Nielsen, B., Damgaard, M., Hansen, J. F., Hansen, S., Helo, O. H, Hildebrandt, P., Hilden, J., Jensen, G. B, Kastrup, J., Kolmos, H. J., Kjoller, E., Lind, I., Nielsen, H., Petersen, L., Gluud, C., CLARICOR Trial Group, (2006). Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 332: 22-27 [Abstract] [Full Text]  
• (2005). Part 12: Pediatric Advanced Life Support. Circulation 112: IV-167-IV-187 [Full Text]  
• Malone, D. C., Hutchins, D. S., Haupert, H., Hansten, P., Duncan, B., Van Bergen, R. C., Solomon, S. L., Lipton, R. B. (2005). Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 62: 1983-1991 [Abstract] [Full Text]  
• Straus, S. M.J.M., Sturkenboom, M. C.J.M., Bleumink, G. S., Dieleman, J. P., Lei, J. v. d., Graeff, P. A. d., Kingma, J. H., Stricker, B. H.Ch. (2005). Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 26: 2007-2012 [Abstract] [Full Text]  
• Granowitz, E. V., Brown, R. B. (2005). Macrolides in Community-Acquired Pneumonia: Does the Bell Toll for Thee?. Chest 128: 1089-1093 [Full Text]  
• Wilkinson, G. R. (2005). Drug Metabolism and Variability among Patients in Drug Response. NEJM 352: 2211-2221 [Full Text]  
• Hewlett, E. L., Edwards, K. M. (2005). Pertussis -- Not Just for Kids. NEJM 352: 1215-1222 [Full Text]  
• Nykamp, D. L, Blackmon, C. L, Schmidt, P. E, Roberson, A. G (2005). QTc Prolongation Associated with Combination Therapy of Levofloxacin, Imipramine, and Fluoxetine. The Annals of Pharmacotherapy 39: 543-546 [Abstract] [Full Text]  
• Reed, M., Wall, G. C, Shah, N. P, Heun, J. M, Hicklin, G. A (2005). Verapamil Toxicity Resulting from a Probable Interaction with Telithromycin. The Annals of Pharmacotherapy 39: 357-360 [Abstract] [Full Text]  
• Kaplan, E. L., Winston, A. P., Schoenholtz, J. C., Harris, J.-D., de Leon-Casasola, O. A., Amory, J. K., Amory, D. W. Sr., Ray, W. A., Murray, K. T., Stein, C. M., Liu, B. A., Juurlink, D. N. (2005). Oral erythromycin and the risk of sudden death.. NEJM 352: 301-304 [Full Text]  
• (2004). Erythromycin Drug Interactions: Rare but Deadly. JWatch Pediatrics 2004: 2-2 [Full Text]  
• (2004). Increased Risk for Sudden Death: Time to Toss Erythromycin from the Formulary. JWatch Emergency Med. 2004: 1-1 [Full Text]  
• (2004). Can Use of Oral Erythromycin Lead to Sudden Cardiac Death?. Journal Watch Cardiology 2004: 1-1 [Full Text]  
• (2004). Oral Erythromycin Increases the Risk for Sudden Cardiac Death. JWatch Infect. Diseases 2004: 1-1 [Full Text]  
• (2004). Erythromycin and Sudden Death. JWatch General 2004: 2-2 [Full Text]